Figure 2 From: The protein C pathway: implications for the design of the RESPOND study Change in protein C levels and 28-day mortality in PROWESS patients [9]. DrotAA, drotrecogin alfa (activated); N, total number of patients in each group; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.Back to article page